Bharat Immunological & Biological Corporation Ltd

Bharat Immunological & Biological Corporation Ltd (BIBCL) is a micro-cap Healthcare company valued at ₹41 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Bharat Immunological & Biological Corporation Ltd last traded at ₹9.55, down 3.63% on the day.

Financial performance

The company's business is deteriorating, with annual revenue falling 42.3% and annual net profit turning into a loss that widened from ₹9 crore to ₹17 crore. The latest quarter saw revenue collapse to ₹0 crore, and net profit loss widened from ₹3 crore to ₹5 crore compared to the same quarter a year earlier.

Valuation multiples

A price-to-earnings ratio is not meaningful here because the company is loss-making; the stock trades at -2.13 times book value.

Things to watch

The company reported a net loss of ₹17 crore in its latest financial year, with net profit margin worsening to -37.8%. Revenue has declined sharply, with a 100.0% drop in the latest quarter compared to the same quarter a year earlier. The net profit loss has widened significantly over the past three years.

Where it stands

The company is in a severe financial decline, with annual net profit turning into a loss that widened from ₹9 crore to ₹17 crore. The latest quarter saw revenue collapse to ₹0 crore, and net profit loss widened to ₹5 crore. The most significant movement is the widening net loss.

Summarised by DocStoX's model on 2026-10-18 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.